About Hemophilia AHemophilia A is a rare, inherited disorder in which a person’s ability to clot is impaired. Hemophilia A occurs in about 1 in 10,000 male births annually and is caused by having substantially reduced or no Factor VIII protein for normal blood clotting for normal blood clotting. People with hemophilia A therefore need injections of factor VIII to restore the coagulation process and prevent frequent bleeds that could otherwise cause pain, irreversible joint damage and life-threatening bleeding. Prophylaxis treatment with infusions three times per week or every other day, maintain a sufficient circulating blood clotting factors is increasingly used, and long-term studies demonstrate that such regimens increase the patient life expectancy and reduce, if not eliminate progressive joint damage.
Biovitrum Advances Novel Factor VIII Long-Acting Hemophilia A Therapy in clinical trialsBiovitrum AB today announced that the first patient in a Phase metered I / IIa clinical trial of long-acting fully-recombinant factor VIII Fc fusion protein. The Phase I / IIa open-label study will evaluate the safety, tolerability and pharmacokinetics of rFVIIIFc in severe, previously treated hemophilia A patients. The rFVIIIFc program and international study with Biogen Idec merged.
As a result, NB – 002 is not absorbed systemically, in early 2008. Phase – 1 trial. In the study, 20 patients with advanced onychomycosis were randomized to two strengths of NB-002 to receive. Treatments were applied twice daily for 28 days to both affected and unaffected toenails and a small area of surrounding skin.Planned, with option to widen the process subscribe up to 24 patients be enrolled in anticipation of the first results. ‘We are pleased with progress of the NTDDS the program Pittsburgh are very excited,’says Elisabeth Lindner, CEO of Diamyd Medical. ‘Prospective treatment to diabetic complications, including neuropathic pain is of strategic interest to Diamyd Medical and complements nicely out our Diamy diabetic vaccines for the to launch a request for a period III study newly was submitted by the FDA. ‘. About Diamyd NTDDS technologies responsible for treating pain.
BMA Scotland regretted Loss of minimum of pricing of alcohol Whilst debate on Bill.. Diamyd MedicalDiamyd Medical announces that it the submission of a IND for NP 2, the company’s first drug candidate Administration his Nerve Targeting Drug Delivery system of gene therapy platform that at the U.S.